• Cancel
    Date：2023-11
    http://www.ceccapitalgroup.com/index.php?a=shows&catid=34&id=767

    This innovative platform specializes in recombinant protein drugs for metabolic diseases. QL Biopharm announces the completion of a nearly 200 million B+ round of financing. IMEIK and China US Green Fund led this financing round, with significant contrib

  • Cancel
    Date：2023-07
    http://www.ceccapitalgroup.com/index.php?a=shows&catid=34&id=763

    In June, Sinovation, the leading domestic neurosurgery intelligent platform for diagnosis and minimally invasive surgery, announced the completion of a super-billion D+ round financing. The investors in this round include Xinda Kunpeng, TsingVentures, Pea

  • Cancel
    Date：2023-06
    http://www.ceccapitalgroup.com/index.php?a=shows&catid=34&id=706

    The round was led by New Alliance Capital and Zhangkeherun Venture Capital, with participation from new investors Rockbleu Capital, Royal Fund, Zhuhai Huajin Capital, and Elikon Venture, and continued support from existing investors Delos Global Investmen

  • Cancel
    Date：2023-04
    http://www.ceccapitalgroup.com/index.php?a=shows&catid=34&id=708

    Columbia China and Nanyan Group announce Nanyan Group's acquisition of Columbia China's clinic business. CEC Capital acted as exclusive financial advisor to Columbia China in this transaction.

  • Cancel
    Date：2023-04
    http://www.ceccapitalgroup.com/index.php?a=shows&catid=34&id=711

    Shanghai Winning Health Software Technology Co., Ltd. ("Winning Health") recently raised RMB 300 million in its Series C financing round. The investment was led exclusively by Taiping Medical and Health Industry Fund, a subsidiary of China Taiping Insuran

  • Cancel
    Date：2023-04
    http://www.ceccapitalgroup.com/index.php?a=shows&catid=34&id=707

    Hangzhou Diagens Biotechnology Co., Ltd. ("Diagens Biotechnology" or "the Company"), a leading reproductive health company in China, recently closed a financing round of RMB 100+ million. This round was led by Grand Flight Investment, with participation f

  • Cancel
    Date：2023-03
    http://www.ceccapitalgroup.com/index.php?a=shows&catid=34&id=710

    Qingdao PHAGEPHARM Biotechnology Co., Ltd. ("PHAGEPHARM" or “Company”), a leading domestic provider of phage-resistant comprehensive solutions, completed a Series B financing round of nearly RMB 100 million. This financing was led by Cenova Capital, with participation from Morningside Ventures and two existing shareholders. CEC Capital served as exclusive financial advisor for this transaction.

  • Cancel
    Date：2023-02

    Exclusive Financial Advisor to Concare

  • Cancel
    Date：2022-12
    http://www.ceccapitalgroup.com/index.php?a=shows&catid=34&id=718

    OYMotion Technologies secured nearly RMB 100 million in its Series C funding round. The funding round was led by Intelligent Interconnection Industry Fund, a subsidiary of Qianhai Ark Industrial Fund, and Zhongyuan Qianhai Fund. XingTuo Capital, Zhang Y